Your session is about to expire
← Back to Search
Monoclonal Antibodies
Novel Drug Combinations for Multiple Myeloma
Phase 1
Recruiting
Research Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)
Eastern Cooperative Oncology Group performance status of 0-1
Must not have
Known active or history of central nervous system (CNS) involvement of MM
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to find an effective, safe dose of drugs to treat multiple myeloma, a cancer of the blood.
Who is the study for?
This trial is for people with multiple myeloma that has come back or didn't respond to treatment. They must have had at least one but not more than three prior treatments and be in good physical condition. People can't join if their cancer has spread to the brain or they have other health issues that could affect the study results.
What is being tested?
The trial is testing BMS-986393 combined with alnuctamab, mezigdomide, and iberdomide to find a safe dose for patients whose multiple myeloma has relapsed or isn't responding to treatment.
What are the potential side effects?
Possible side effects of these drugs may include fatigue, digestive problems, blood disorders, increased risk of infections, and reactions at the infusion site. The exact side effects will depend on how well participants tolerate BMS-986393.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have multiple myeloma that has come back or didn't respond to treatment, and I've had 1-3 prior treatments.
Select...
I am fully active or can carry out light work.
Select...
My multiple myeloma can be measured.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My multiple myeloma has affected or previously affected my brain or spinal cord.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Arm C: BMS-986393 + IberdomideExperimental Treatment2 Interventions
Group II: Arm B: BMS-986393 + MezigdomideExperimental Treatment2 Interventions
Group III: Arm A: BMS-986393 + AlnuctamabExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Iberdomide
2021
Completed Phase 1
~60
Mezigdomide
2023
Completed Phase 1
~40
Find a Location
Who is running the clinical trial?
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyLead Sponsor
15 Previous Clinical Trials
2,056 Total Patients Enrolled
6 Trials studying Multiple Myeloma
787 Patients Enrolled for Multiple Myeloma
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,582 Previous Clinical Trials
3,388,490 Total Patients Enrolled
77 Trials studying Multiple Myeloma
29,008 Patients Enrolled for Multiple Myeloma